Dyadic International, Inc.
Dyadic International, Inc. (DYAI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DYAI · as of Sep 30, 2025
Ownership Breakdown
37
Institutional Holders
▼ 1 vs Q2
$6.93M
Total Inst. Value
▲ $2.02M vs Q2
36.44M
Shares Outstanding
freeFloat 74.33%
5.87M
13F Shares Held
▲ 908,374 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DYAI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
APIS CAPITAL ADVISORS, LLC biological products, (no diagnostic substances) | 1.54M | 5.12% | 5.12% | $1.82B | Nov 14, 2025 | NEW |
CHAPIN DAVIS, INC. biological products, (no diagnostic substances) | 932.0K | 3.10% | 3.10% | $1.10B | Oct 9, 2025 | ▲ 49.2K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 915.0K | 3.04% | 3.04% | $1.08B | Nov 7, 2025 | ▲ 54.3K |
PERKINS CAPITAL MANAGEMENT INC biological products, (no diagnostic substances) | 348.1K | 1.16% | 1.16% | $410.70M | Oct 31, 2025 | ▲ 300.2K |
TRUIST FINANCIAL CORP biological products, (no diagnostic substances) | 326.2K | 1.08% | 1.08% | $384.92M | Nov 3, 2025 | ▲ 76.2K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 265.4K | 88.17% | 88.17% | $313.25M | Nov 12, 2025 | ▲ 6.3K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 254.5K | 84.55% | 84.55% | $300.32M | Nov 12, 2025 | ▲ 1.5K |
CI PRIVATE WEALTH, LLC biological products, (no diagnostic substances) | 250.0K | 83.05% | 83.05% | $295.00M | Nov 14, 2025 | NEW |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 165.1K | 54.85% | 54.85% | $194.82M | Nov 13, 2025 | ▲ 117.5K |
LANDSCAPE CAPITAL MANAGEMENT, L.L.C. biological products, (no diagnostic substances) | 160.7K | 53.37% | 53.37% | $189.57M | Nov 13, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
8
Increased
+610.6K shares8
New Positions
first time holders5
Decreased
−9.2K shares8
Sold Out
fully exitedNet shares change (top 50)
+601.4K
+610.6K / −9.2K
Net new holders
+3
8 new / 8 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DYAI insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
TCHELET RONEN VP of Research and Bus. Dvlpmt | Jan 2, 2026 | Award | 18,064 | — | — | 50.9K | Form 4 ↗ |
TCHELET RONEN VP of Research and Bus. Dvlpmt | Jan 2, 2026 | Award | 47,250 | $0.94 | $44.4K | 47.3K | Form 4 ↗ |
Rawson Ping Wang Chief Financial Officer | Jan 2, 2026 | Award | 29,158 | — | — | 170.2K | Form 4 ↗ |
Rawson Ping Wang Chief Financial Officer | Jan 2, 2026 | Award | 47,250 | $0.94 | $44.4K | 47.3K | Form 4 ↗ |
Lucy Patrick K. director | Jan 2, 2026 | Award | 67,500 | $0.94 | $63.5K | 67.5K | Form 4 ↗ |
Kaye Jack director | Jan 2, 2026 | Award | 67,500 | $0.94 | $63.5K | 67.5K | Form 4 ↗ |
HERBST SETH director | Jan 2, 2026 | Award | 50,000 | $0.94 | $47.0K | 50.0K | Form 4 ↗ |
Hazelton Joseph P President & COO | Jan 2, 2026 | Award | 36,418 | — | — | 191.8K | Form 4 ↗ |
Hazelton Joseph P President & COO | Jan 2, 2026 | Award | 67,250 | $0.94 | $63.2K | 67.3K | Form 4 ↗ |
EMALFARB MARK A CEO | Jan 2, 2026 | Award | 102,609 | — | — | 4.83M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Dyadic International, Inc. (DYAI) is primarily owned by institutional investors, who hold approximately 16.1% of total shares outstanding. Company insiders own approximately 25.67%, while retail and public investors account for the remaining 58.22%.
The largest institutional shareholder of Dyadic International, Inc. is APIS CAPITAL ADVISORS, LLC, holding approximately 1.54 million shares — equal to 5.12% of outstanding shares — as of September 30, 2025.
A total of 37 institutional investors currently hold DYAI stock, with a combined institutional value of approximately $6,926,711 as of the most recent 13F filing period.
Frequently asked questions
DYAI ownershipDyadic International, Inc. (DYAI) is primarily owned by institutional investors, who hold approximately 16.1% of shares. The largest shareholder is APIS CAPITAL ADVISORS, LLC with a 5.12% stake. Company insiders hold 25.67%. Data sourced from SEC Form 13F as of September 30, 2025.